SpyGlass Pharma Adds M&A Veteran as General Counsel Amid Phase 3 Trials

Event summary

  • Shannon Treviño appointed General Counsel of SpyGlass Pharma on June 15, 2026.
  • Treviño previously led legal and compliance at Inari Medical during its $4.9 billion acquisition by Stryker.
  • SpyGlass Pharma is advancing its BIM-IOL System through Phase 3 trials for glaucoma treatment.
  • The BIM-IOL System aims to deliver three years of bimatoprost via a non-bioerodible drug pad attached to an intraocular lens.

The big picture

SpyGlass Pharma's appointment of Shannon Treviño as General Counsel underscores its strategic focus on scaling through regulatory milestones and potential commercialization. Treviño's background in high-value healthcare acquisitions suggests SpyGlass may be positioning itself for future M&A activity or partnerships as it advances its lead product candidate. The move comes at a critical juncture for the company, with Phase 3 trials underway for its innovative glaucoma treatment system.

What we're watching

Regulatory Pathway
Whether SpyGlass Pharma can successfully navigate FDA approval for the BIM-IOL System.
Execution Risk
The pace at which Phase 3 trials progress and enroll patients.
Strategic Leadership
How Treviño's M&A experience will influence SpyGlass Pharma's growth and potential partnerships.